Breaking News

Metsera Launches with Focus on Medicines for Obesity & Metabolic Diseases

Advances a portfolio of oral and injectable incretin, non-incretin and combination therapies designed to address multiple targets.

Author Image

By: Charlie Sternberg

Associate Editor

Metsera Inc., a clinical-stage biopharmaceutical company accelerating medicines for obesity and metabolic diseases, has officially launched. Founded by Population Health Partners and ARCH Venture Partners and led by former executives of The Medicines Company, Metsera is advancing a portfolio of oral and injectable incretin, non-incretin and combination therapies designed to address multiple targets and meet the future needs of a rapidly evolving weight loss treatment landscape.   “Metsera was ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters